Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294). Therefore, it would not be an efficient use of NHS resources to conduct an evaluation. Aflibercept 8mg should therefore be considered for routine commissioning.
ID number 10590

Project Team

Project lead Danielle Lees

Email enquiries

For further information on how we select topics for development, please see our page about topic selection